AIFA Agenzia Italiana del Farmaco
Modify Veklury Register (remdesivir) early treatment
Users of the Drug Registries subject to Monitoring are informed that, following the CTS decision, the Registry of the medicinal product Veklury (remdesivir), under the NHS reimbursement regimen, has been amended for the following therapeutic indication:
Treatment of coronavirus disease 2019 (COVID-19), adult and adolescent patients aged 12 years and older (and weighing at least 40 kg), not hospitalized for COVID-19 and not on oxygen therapy for COVID-19 with onset of symptoms for no more than 7 days and in the presence of predisposing clinical conditions that represent risk factors for the development of severe Covid-19.
The Registry will also allow the treatment of patients aged 12 years and over (and weighing at least 40Kg); In addition, retreatment is authorised where the patient has not already been treated with the same or another antiviral for the same infectious episode or in the previous 4 weeks.
The prescriptions relating only to the indications reimbursed by the National Health Service, through the aforementioned publication, must be carried out in accordance with the criteria of eligibility and prescriptive appropriateness reported in the clinical card, downloadable from the list of «Active Registers and PT», accessible from the «Related links» box.
Finally, it is specified that, starting from the modified «VEKLURY — Early treatment» register is available on the web platform.
Monitoring Registers Office
Published on:
— Reproduction reserved and for personal use
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum number of visits
Source — https://www.univadis.it/viewarticle/modifica-registro-veklury-remdesivir-trattamento-precoce